Rivanna receives FDA clearance of its Accuro device

127

Rivanna Medical has received US Food and Drug Administration 510(k) clearance to market Accuro, a handheld and untethered smart phone-sized ultrasound device that is designed to guide spinal anaesthesia with automated 3D navigation technology.

The Accuro platform is designed to provide automated navigation to an anatomical target so a clinician can avoid guessing where the target is. The initial commercial application of the platform is designed for guiding clinicians to a first-attempt success in administering spinal anaesthesia.

“There are multiple clinical uses for Accuro, a disruptive, game-changing device platform technology,” said John A Williams, Rivanna president and chief executive officer. “Because of the considerable unmet clinical need for automated image guidance in general, and in the spinal anaesthesia market especially, we are looking forward to launching Accuro.”